These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 2432676)

  • 41. [Disorders of thrombin interaction with the blood vessel wall and its inactivation by antithrombin III in experimental nephrotic syndrome].
    Bashkov GV
    Biull Eksp Biol Med; 1990 Aug; 110(8):133-6. PubMed ID: 2291954
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Probing plasma clearance of the thrombin-antithrombin complex with a monoclonal antibody against the putative serpin-enzyme complex receptor-binding site.
    Long GL; Kjellberg M; Villoutreix BO; Stenflo J
    Eur J Biochem; 2003 Oct; 270(20):4059-69. PubMed ID: 14519117
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of progressive antithrombin activity and the concentration of three thrombin inhibitors in nephrotic syndrome.
    Boneu B; Bouissou F; Abbal M; Sie P; Caranobe C; Barthe P
    Thromb Haemost; 1981 Oct; 46(3):623-5. PubMed ID: 6171906
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Anticoagulating activity and lytic action of the heparin-antithrombin III and antithrombin III-heparin-thrombin complexes on non-stabilized fibrin].
    Kudriashov BA; Pastorova VE; Liapina LA
    Biokhimiia; 1981 Nov; 46(11):2024-9. PubMed ID: 7317530
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Preparation and characterization of monoclonal antibodies against the human thrombin-antithrombin III complex.
    Asakura S; Yoshida N; Matsuda M; Murayama H; Soe G
    Biochim Biophys Acta; 1988 Jan; 952(1):37-47. PubMed ID: 3422029
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Inducing conformational changes in thrombin by ligands as a way of regulating its activity].
    Gershkovich AA
    Biokhimiia; 1996 Jul; 61(7):1139-51. PubMed ID: 9035728
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of low molecular weight heparin on a severely antithrombin III-decreased disseminated intravascular coagulation model in rabbits.
    Tazawa S; Ichikawa K; Misawa K; Fukuyama J; Hamano S; Miyata H; Sakuragawa N
    Thromb Res; 1995 Dec; 80(5):391-8. PubMed ID: 8588200
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In vivo behaviour of some antithrombin III-protease complexes.
    Lam LS; Regoeczi E; Hatton MW
    Br J Exp Pathol; 1979 Apr; 60(2):151-60. PubMed ID: 156039
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Regulation of the thrombin time in cirrhosis.
    Braunstein KM; Kinard HB; Hepfer TW; Craig WR; Eurenius K
    Thromb Res; 1976 Oct; 9(4):301-17. PubMed ID: 136058
    [No Abstract]   [Full Text] [Related]  

  • 50. Specific binding of thrombin-antithrombin III complex to hepatocytes.
    Bauer PI; Mandl J; Machovich R; Antoni F; Garzo T; Horváth I
    Thromb Res; 1982 Dec; 28(5):595-606. PubMed ID: 6220483
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dissociation of antithrombin III--thrombin complex. Formation of active and inactive antithrombin III.
    Griffith MJ; Lundblad RL
    Biochemistry; 1981 Jan; 20(1):105-10. PubMed ID: 7470462
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Serial thrombolysis-related changes after thrombolytic therapy with TPA in patients with acute myocardial infarction.
    Ho CH; Wang SP
    Thromb Res; 1990 May; 58(3):331-41. PubMed ID: 1693793
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Binding of thrombin to thrombomodulin accelerates inhibition of the enzyme by antithrombin III. Evidence for a heparin-independent mechanism.
    Preissner KT; Delvos U; Müller-Berghaus G
    Biochemistry; 1987 May; 26(9):2521-8. PubMed ID: 3038185
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Normal antithrombin-III activity and concentration in experimental disseminated intravascular coagulation.
    Müller-Berghaus G; Niepoth M; Rabens-Alles B; Rump E; Murano G
    Scand J Clin Lab Invest Suppl; 1985; 178():107-13. PubMed ID: 3867111
    [No Abstract]   [Full Text] [Related]  

  • 55. [Fibrinogen and antithrombin III in obese subjects].
    Ferlito S; Palermo A; Mazzone D; Condorelli M; Papalia D
    Minerva Endocrinol; 1990; 15(2):145-8. PubMed ID: 2098657
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Regulation of factor IXa in vitro in human and mouse plasma and in vivo in the mouse. Role of the endothelium and the plasma proteinase inhibitors.
    Fuchs HE; Trapp HG; Griffith MJ; Roberts HR; Pizzo SV
    J Clin Invest; 1984 Jun; 73(6):1696-703. PubMed ID: 6202716
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Decreased plasma fibrinolysis in patients with rheumatoid arthritis.
    Belch JJ; McArdle B; Madhok R; McLaughlin K; Capell HA; Forbes CD; Sturrock RD
    Ann Rheum Dis; 1984 Dec; 43(6):774-7. PubMed ID: 6084477
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Plasma antithrombins and thrombin binding to platelets in plasma.
    Rotoli B; Majerus PW
    Haematologica; 1979 Oct; 64(5):537-51. PubMed ID: 92440
    [No Abstract]   [Full Text] [Related]  

  • 59. Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy.
    Hogg PJ; Jackson CM
    Proc Natl Acad Sci U S A; 1989 May; 86(10):3619-23. PubMed ID: 2726739
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The heparin-accelerated neutralisation of bovine alpha and beta thrombins by antithrombin III.
    MacGregor IR; Lane DA; Kakkar VV
    Biochim Biophys Acta; 1980 Sep; 632(1):131-7. PubMed ID: 7417517
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.